BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat consensus” on total revenue and EPS. The firm likes the company’s relative lack of major patent expiries until the early 2030s and feels anchor brand Biktarvy could help Gilead continue to be a “beat and raise” story, the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Ideaya Biosciences enters additional supply pact with Gilead for IDE397
- Gilead Sciences: Strong Financial Performance and Promising Future Prospects Drive Optimistic Outlook
- Gilead upgraded to Buy from Hold at DZ Bank
- Gilead Sciences: Strong Performance and Growth Potential in HIV and Oncology Segments Boost Buy Rating
- Gilead Sciences’ Earnings Call: Strong Growth Amid Challenges